BJDX
Bluejay Diagnostics, Inc. (BJDX) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Momentum (D). The rating has held at C for 6 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-17 | B+ (3.7) | C+ (2.5) | C- (2.1) | D (1.2) | C+ (2.6) | C (2.4) |
| 2026-11-10 | B+ (3.8) | C+ (2.5) | C- (2.1) | D (1.2) | C+ (2.6) | C (2.4) |
| 2026-11-03 | B+ (3.7) | C+ (2.5) | C- (2.1) | D- (1.0) | C+ (2.7) | C (2.4) |
| 2026-10-27 | B+ (3.6) | C+ (2.5) | C- (2.1) | D- (1.0) | C+ (2.6) | C (2.4) |
| 2026-10-20 | B+ (3.6) | C+ (2.5) | C- (2.1) | D- (1.1) | C+ (2.6) | C (2.4) |